Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
1,108.09
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today
↗
Today 3:37 EST
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains
↗
January 07, 2026
Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.
Via
Stocktwits
Topics
Initial Public Offering
Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal
↗
January 07, 2026
Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40%.
Via
Investor's Business Daily
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
January 07, 2026
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Eli Lilly Stock Rises After Hours On UBS ‘Buy’ Call Ahead Of Oral Obesity Pill Launch — GLP-1 Battle With Novo Heats Up
↗
January 06, 2026
Via
Stocktwits
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
January 07, 2026
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...
Via
MarketMinute
Topics
Economy
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal
↗
January 07, 2026
Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.
Via
Stocktwits
3 Drug Stocks to Buy at a Discount
↗
January 07, 2026
The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.
Via
The Motley Fool
The Valuation Wall: Nasdaq Momentum Stalls as the 'Great Rotation' of 2026 Takes Hold
January 07, 2026
The relentless surge that propelled the technology sector to historic heights throughout 2024 and 2025 has hit a significant roadblock in the opening week of 2026. As of January 7, 2026, the tech-heavy...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The Great Rotation: How the 2026 Market Rally Outgrew the 'Magnificent Seven'
January 07, 2026
As the first week of trading in 2026 comes to a close, the S&P 500 has once again shattered records, crossing the 7,500 threshold with a momentum that feels fundamentally different from the...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
This Could Be Key to Pfizer's Turnaround in 2026
↗
January 07, 2026
Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.
Via
The Motley Fool
Topics
Intellectual Property
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition
↗
January 07, 2026
Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.
Via
Benzinga
Discover which S&P500 stocks are making waves on Wednesday.
↗
January 07, 2026
Via
Chartmill
The Alpha Renaissance: Goldman Sachs Reports Record Hedge Fund Gains in 2025
January 07, 2026
In a landmark year for active management, Goldman Sachs (NYSE: GS) has released its comprehensive 2025 year-end report, revealing that the hedge fund industry staged a dramatic comeback, delivering...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Why Did Eli Lilly Shares Surge Today? Key Factors
↗
January 07, 2026
Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.
Via
Talk Markets
Eli Lilly (LLY) Stock Is Up, What You Need To Know
January 07, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in...
Via
StockStory
Topics
Artificial Intelligence
My Top 5 Stocks to Buy in Early 2026
↗
January 07, 2026
These companies are leaders in their fields.
Via
The Motley Fool
Topics
Artificial Intelligence
Ventyx (VTYX) Shares Soar 62.5% Overnight, Here's What's Going On With This Trending Stock
↗
January 06, 2026
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.
Via
Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
↗
January 06, 2026
Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.
Via
The Motley Fool
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?
↗
January 06, 2026
Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?
Via
The Motley Fool
Topics
Intellectual Property
Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover
↗
January 06, 2026
Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.
Via
Investor's Business Daily
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
January 06, 2026
As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...
Via
MarketMinute
Topics
Economy
S&P 500 Shatters Records: Index Crosses 6,944 as Tech Giants and Healthcare Titans Lead the Charge
January 06, 2026
The S&P 500 reached a historic milestone on January 6, 2026, closing at a new all-time high of 6,944.82. This 0.6% gain on the first full trading week of the year signals a powerful continuation of the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout
↗
January 06, 2026
A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter.
Via
Stocktwits
Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI
↗
January 06, 2026
Under the deal, Nimbus is eligible to receive up to $1.3 billion.
Via
Stocktwits
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
January 06, 2026
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
January 06, 2026
As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
↗
January 06, 2026
Eli Lilly offers investors safety and growth.
Via
The Motley Fool
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss
↗
January 06, 2026
Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.
Via
Investor's Business Daily
Motley Fool Money: Stock Market Naughty and Nice List
↗
January 06, 2026
There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.